TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing Summary TRPV1 inhibition can enhance the effectiveness of PD-1 blockade immunotherapy in treating tumors. Tumors can develop resistance to cytotoxic T lymphocyte (Read More